Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel
NASDAQ:ACXP

Acurx Pharmaceuticals Q3 2026 Earnings Date & Estimates

Acurx Pharmaceuticals logo
$1.06 0.00 (0.00%)
Closing price 11/9/2026 04:00 PM Eastern
Extended Trading
$1.09 +0.03 (+2.45%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Acurx Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Acurx Pharmaceuticals in Q3 2026

Acurx Pharmaceuticals is expected to post earnings of -$0.45 per share. In the same quarter a year earlier Acurx Pharmaceuticals reported -$1.23 per share. Acurx Pharmaceuticals last reported on August 13, 2026, posting -$0.53 per share and missing the -$0.3767 consensus estimate. Acurx Pharmaceuticals has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.45
Prior-Year EPS
-$1.23

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.53 (Missed by -$0.1533)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Acurx Pharmaceuticals Q3 2026 Earnings FAQ

Acurx Pharmaceuticals (NASDAQ:ACXP) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Acurx Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Acurx Pharmaceuticals to post earnings of -$0.45 per share for Q3 2026.

Acurx Pharmaceuticals Earnings Headlines

Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Thursday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179186
Acurx Pharmaceuticals Lowers Quorum for Shareholder Meetings
October 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/acurx-pharmaceuticals-lowers-quorum-for-shareholder-meetings?utm_source=marketbeat.com&utm_medium=referral
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
 |  Weiss Ratings (Ad)
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
October 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-discuss-third-quarter-2026-financial-results-on-november-12-2026-conference-call-and-provide-business-update-302917686.html
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
October 21, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/acurx-announces-publication-in-asm-confirming-data-on-its-dna-pol-iiic-inhibitor-pipeline-of-antibiotics-demonstrating-a-potential-microbiome-sparing-class-effect-302914900.html
Acurx Pharmaceuticals Shareholders Approve Governance and Auditing Changes
October 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/acurx-pharmaceuticals-shareholders-approve-governance-and-auditing-changes?utm_source=marketbeat.com&utm_medium=referral
See More Acurx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acurx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acurx Pharmaceuticals and other key companies, straight to your email.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals (NASDAQ:ACXP) (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on therapies designed to address pathogens that are resistant to existing treatments.

Acurx’s lead product candidate is ibezapolstat, also known as ACX-375, an investigational oral antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile infection. The drug is designed to inhibit bacterial DNA polymerase IIIC, an enzyme involved in bacterial DNA replication, while potentially preserving beneficial bacteria in the gut.

The company’s development programs are focused primarily on the U.S. market and remain subject to clinical testing and regulatory review. Acurx is headquartered in New York and continues to advance ibezapolstat through clinical development while evaluating the broader potential of its antibiotic discovery platform.

View Acurx Pharmaceuticals Profile
Earnings Tools